Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Atazanavir
Drug ID BADD_D00176
Description Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once-daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003.
Indications and Usage Used in combination with other antiretroviral agents for the treatment of HIV-1 infection, as well as postexposure prophylaxis of HIV infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with HIV when that exposure represents a substantial risk for HIV transmission.
Marketing Status Prescription; Discontinued
ATC Code J05AE08
DrugBank ID DB01072
KEGG ID D07471
MeSH ID D000069446
PubChem ID 148192
TTD Drug ID D07IQS
NDC Product Code 42385-921; 65862-713; 0003-3631; 70518-1365; 70710-1052; 70771-1591; 65862-710; 69097-443; 0003-3622; 69097-444; 65862-711; 11014-0175; 69097-446; 70771-1592; 69238-1137; 16714-860; 31722-654; 42385-922; 42385-920; 0003-3638; 70771-1593; 70710-1051; 0003-3624; 31722-653; 65862-712; 69097-445; 31722-655; 69238-1136; 16714-861; 69238-1138; 70710-1050; 69238-1135; 16714-862; 70518-2832; 0904-6875
Synonyms Atazanavir Sulfate | Reyataz | Atazanavir | 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-2,5,6,10,13-pentaazatetradecanedioic acid dimethyl ester | CGP 75176 | CGP75176 | CGP-75176 | CGP 73547 | CGP-73547 | CGP73547 | CGP 75355 | CGP75355 | CGP-75355 | CGP 75136 | CGP75136 | CGP-75136 | BMS-232632-05 | BMS 232632 05 | BMS23263205 | BMS 232632 | 232632, BMS | BMS-232632 | BMS232632
Chemical Information
Molecular Formula C38H52N6O7
CAS Registry Number 198904-31-3
SMILES CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)N C(=O)OC)O)NC(=O)OC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rash generalised23.03.13.0020.005512%Not Available
Rash maculo-papular23.03.13.004--
Rash pustular23.03.10.003; 11.01.12.002--
Renal disorder20.01.02.0020.013780%Not Available
Renal failure20.01.03.0050.005033%Not Available
Renal pain20.02.03.003--Not Available
Respiratory disorder22.02.07.0020.008268%Not Available
Rhinorrhoea22.02.05.010--
Seborrhoeic dermatitis23.03.04.018--Not Available
Seizure17.12.03.001--
Sepsis11.01.11.0030.005752%
Septic shock24.06.02.011; 11.01.11.0040.001438%Not Available
Shock24.06.02.002--Not Available
Skin disorder23.03.03.007--Not Available
Sleep disorder19.02.04.001--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Staphylococcal scalded skin syndrome23.03.01.025; 11.02.05.010--Not Available
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 11.07.01.005; 10.01.03.020--
Stomatitis07.05.06.005--
Suicide attempt19.12.01.004--
Syncope24.06.02.012; 17.02.04.008; 02.01.02.008--
Tension19.06.02.005--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Toothache07.09.06.001--
Torsade de pointes02.03.04.005--Not Available
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Urinary tract infection11.01.14.004; 20.08.02.001--
Urine abnormality20.02.01.013--Not Available
Urticaria23.04.02.001; 10.01.06.001--
The 7th Page    First    Pre   7 8 9    Next   Last    Total 9 Pages